BNB PLUS CORP. (BNBX)
BNB Plus Corp., established in 1983 and based in Stony Brook, NY, is a biotechnology firm dedicated to pioneering and commercializing technologies for the synthesis and identification of both deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). The company's operations are divided into three distinct business segments. Its Therapeutic DNA Production Services division specializes in the enzymatic manufacturing of synthetic DNA, used in the creation of nucleic acid-based treatments, and also develops and markets its proprietary RNA Polymerase (RNAP) for mRNA therapeutic production. The MDx Testing Services segment concentrates on developing clinical molecular diagnostic and genetic assessments, in addition to providing comprehensive clinical laboratory testing services. Lastly, the DNA Tagging and Security Products and Services segment leverages DNA detection techniques for securing industrial supply chains and offering various security solutions.
Sector: Finance Services
Industry: Biotechnology
BNB Plus Corp.
+6.25%$0.1275
After Hours+0.00%$0.1275
AH+0.00%$0.1275
OTC:BNBXHealthcare
Mkt Cap$790K
Float4.83M
O/S6.2M
Inst Own7.9%
SI0.1%
Dilution
Delisting Issues Timeline
Financials Summary
Revenue$2.14M
Net Income-$15.16M
Total Assets$4.44M
Free Cash Flow-$12.83M
Debt & Equity
Equity 100%
Total Debt$0
Total Equity$12.51M
Shares Outstanding
Short Interest
Split History1 split · 1 reverse
2-year cumulative
1:15
Nasdaq bars a compliance period at 1:250
- 1:15Reverse splitJun 2, 202515 shares → 1
Balance Sheet Details
Assets$13.63M
Liabilities$1.5M
Accounts Receivable$303K
Accounts Payable$840K
Inventory$115K
PP&E (Net)$174K
Goodwill$0
Intangible Assets$1.34M
Income Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD |
| Period Ending | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
| Revenue | $2.14M | $3.43M | $13.37M | $18.17M | $9.03M |
| YoY Growth | -3772.4% | -7433.0% | -2642.6% | 10125.4% | - |
| Cost of Revenue | $1.3M | $2.41M | $7.83M | $13.12M | $4.54M |
| Gross Profit | $839K | $1.02M | $5.53M | $5.05M | $4.48M |
| Gross Margin | 3925.7% | 2963.4% | 4139.5% | 2781.5% | 4965.7% |
| Research and Development | $6.02M | $3.59M | $3.74M | $3.93M | $4.16M |
| Selling, General, and Administrative | $10.87M | $11.45M | $12.75M | $15.1M | $12.85M |
| Other | $0 | $0 | $0 | $0 | $822K |
| Total Operating Expenses | $16.89M | $15.04M | $16.49M | $19.02M | $17.83M |
| Operating Income (EBIT) | -$16.05M | -$14.02M | -$10.95M | -$13.97M | -$13.35M |
| Operating Margin | -75091.6% | -40871.6% | -8194.0% | -7688.9% | -14786.3% |
| Interest Expense | $0 | $0 | $0 | $0 | $0 |
| Interest Income | $193K | $176K | $75K | $7K | $14K |
| Other Income (Expense) | $406K | $6.94M | $930K | $5.7M | -$930K |
| Income Before Tax (EBT) | -$15.64M | -$7.09M | -$10.02M | -$8.27M | -$14.28M |
| Income Tax Expense | -$684K | $0 | $0 | $0 | $0 |
| Net Income | -$15.16M | -$6.99M | -$9.95M | -$8.27M | -$14.29M |
| Net Income Margin | -70946.1% | -20377.9% | -7441.3% | -4550.6% | -15825.1% |
| Supplementary Data | |||||
| EPS | -134.23 | -68.25 | -570.37 | -9741.86 | -28630.14 |
| Diluted EPS | -134.23 | -68.25 | -570.37 | -9741.86 | -28630.14 |
| Weighted Average OS | 517,671 | 105,760 | 17,433 | 860 | 499 |
| EBITDA | -$15.26M | -$6.39M | -$8.66M | -$6.98M | -$11.68M |
| EBITDA Margin | -71394.1% | -18627.5% | -6478.9% | -3841.5% | -12940.6% |
Balance Sheet
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD |
| Period Ending | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
| Assets | |||||
| Current Assets | |||||
| Cash and Cash Equivalents | $1.67M | $6.43M | $7.15M | $15.22M | $6.55M |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 |
| Cash and Short-Term Investments | $1.67M | $6.43M | $7.15M | $15.22M | $6.55M |
| Accounts Receivable | $237K | $362K | $256K | $3.07M | $2.8M |
| Inventory | $84K | $439K | $330K | $602K | $1.37M |
| Other Current Assets | $249K | $816K | $389K | $0 | $0 |
| Total Current Assets | $2.24M | $8.05M | $8.13M | $19.94M | $11.3M |
| Long-Term Assets | |||||
| Property, Plant & Equipment Net | $436K | $1.29M | $2.08M | $2.22M | $3.02M |
| Goodwill | $0 | $0 | $0 | $0 | $0 |
| Intangible Assets | $0 | $2.7M | $2.7M | $0 | $0 |
| Long-Term Investments | $750K | $0 | $0 | $0 | $0 |
| Deferred Tax Assets | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Assets | $1.01M | $750K | $750K | $99K | $95K |
| Total Long-Term Assets | $2.2M | $4.74M | $5.53M | $2.32M | $3.12M |
| Other Assets | $0 | $0 | $0 | $0 | $0 |
| Total Assets | $4.44M | $12.79M | $13.65M | $22.27M | $14.42M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | $845K | $1.17M | $1.07M | $1.74M | $2.01M |
| Short-Term Debt | $0 | $0 | $0 | $0 | $0 |
| Current Income Tax Payable | $0 | $0 | $0 | $0 | $0 |
| Current Unearned Revenue | $12K | $59K | $76K | $564K | $281K |
| Other Current Liabilities | $285K | $0 | $0 | $0 | $0 |
| Total Current Liabilities | $2.46M | $2.4M | $2.85M | $4.19M | $3.27M |
| Long-Term Liabilities | |||||
| Long-Term Debt | $0 | $0 | $0 | $0 | $0 |
| Long-Term Unearned Revenue | $0 | $194K | $194K | $0 | $0 |
| Long-Term Deferred Tax Liabilities | $0 | $684K | $684K | $0 | $0 |
| Other Long-Term Liabilities | $32K | $351K | $4.32M | $5.17M | $31K |
| Total Long-Term Liabilities | $32K | $1.42M | $5.93M | $5.17M | $31K |
| Other Liabilities | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $2.5M | $3.82M | $8.78M | $9.36M | $3.3M |
| Stockholders' Equity | |||||
| Preferred Stock | $0 | $0 | $0 | $0 | $0 |
| Common Stock | $2K | $10K | $683 | $13K | $7K |
| Retained Earnings | -$379.16M | -$309.67M | -$302.45M | -$292.5M | -$284.12M |
| Comprehensive Income & Other | $0 | $0 | $0 | $0 | $0 |
| Other Stockholders' Equity | $381.46M | $318.81M | $307.4M | $305.4M | $295.23M |
| Total Equity | $2.3M | $9.14M | $4.95M | $12.91M | $11.11M |
| Minority Interest | -$363K | -$175K | -$79K | -$3K | -$722 |
| Total Liabilities and Equity | $4.8M | $12.96M | $13.73M | $22.27M | $14.42M |
| Supplementary Data | |||||
| Total Debt | $193K | $739K | $1.24M | $0 | $0 |
| Net Debt | -$1.47M | -$5.69M | -$5.91M | -$15.22M | -$6.55M |
Cash Flow Statement
| Period | FY 2025 |
|---|---|
| Currency | USD |
| Period Ending | 2025-09-30 |
| Operating Activities | |
| Net Income | -$14.96M |
| Depreciation & Amortization | $384K |
| Deferred Income Tax | -$684K |
| Stock-Based Compensation | $102K |
| Changes in Working Capital: | |
| Accounts Receivable | -$6K |
| Inventory | $349K |
| Accounts Payable | $0 |
| Other Working Capital | $38K |
| Total Working Capital Change | $381K |
| Other Non-Cash Items | $2.25M |
| Net Cash from Operating | -$12.52M |
| Investing Activities | |
| Capital Expenditures | -$313K |
| Acquisitions | $0 |
| Purchases of Investments | $0 |
| Sales of Investments | $0 |
| Other Investing Activities | $21K |
| Net Cash from Investing | -$292K |
| Financing Activities | |
| Debt Repaid | - |
| Common Stock Issuance | $8.22M |
| Common Stock Repurchases | $0 |
| Dividends Paid | $0 |
| Other Financing Activities | -$166K |
| Net Cash from Financing | $8.05M |
| Forex Effect | $0 |
| Net Change in Cash | -$4.76M |
| Supplementary Data | |
| Operating Cash Flow | -$12.52M |
| Capital Expenditure | -$313K |
| Free Cash Flow | -$12.83M |
| Cash at Beginning | $7.18M |
| Cash at End | $2.42M |